Vaccine Info

M72/AS01E (M72) Tuberculosis Vaccine

Authored by
Staff
Last reviewed
March 18, 2024
Share

M72/AS01E (M72) Tuberculosis Vaccine Candidate Clinical Trials, Dosage, News, Side Effects, Usage

M72/AS01E (M72) is a subunit vaccine candidate that contains the M72 recombinant fusion protein derived from two Mycobacterium tuberculosis (Mtb) antigens (Mtb32A and Mtb39A) combined with the GlaxoSmithKline plc (GSK) proprietary Adjuvant System AS01. The Mtb39A and Mtb32A components of the recombinant antigen elicited specific lymphoproliferation and/or interferon-gamma (IFN-γ) production in individuals with latent and active TB. AS01E is the adjuvant in GSK's Shingrix® shingles and Mosquirix™ (RTS,S) vaccines. M72/AS01E is indicated to prevent Pulmonary Tuberculosis (TB) in adolescents and adults.

The M72/AS01E vaccine candidate was developed by GSK in partnership with AERAS since the early 2000s. It was developed by GSK up to the proof-of-concept phase of the Phase IIb study. In the Phase IIb trial, M72 showed approximately 50% efficacy in reducing pulmonary TB in adults with latent TB infection. In July 2019, the World Health Organization (WHO) convened in Geneva, Switzerland, to generate consensus on the clinical development pathway for the M72/AS01E vaccine candidate. In 2020, the Bill & Melinda Gates Foundation out-licensed M72/AS01E to the Gates Medical Research Institute (Gate MRI).

In a Phase 2b clinical trial, this vaccine candidate provided approximately 54% protection against progression to active pulmonary tuberculosis for three years in TB-infected HIV-negative adults. On June 28, 2023, Wellcome and the Bill & Melinda Gates Foundation announced funding to advance M72/AS01E (M72) through a Phase III clinical trial. To support the M72 Phase III clinical trial, which will cost an estimated $550 million, Wellcome is providing up to US$150 million, and the GatesMRI will fund the remainder, about $400 million.

M72/AS01E (M72) Tuberculosis Vaccine Indication

TB is estimated that 25% of the global population is estimated to be infected with Mycobacterium tuberculosis, and tuberculosis is the leading infectious cause of death worldwide. 

M72/AS01E (M72) Tuberculosis Vaccine Dosage

M72/AS01E two doses are administered intramuscularly in the deltoid region of the arm.

M72/AS01E (M72) Tuberculosis Vaccine News

November 16, 2023 - Nicole Frahm, Ph.D. Head of Biomarker Development presented Immune Correlates of Protection for BCG and M72 TB Vaccines.

November 16, 2023 - Linda Han, MD, MPH, presented: Safety and immunogenicity of the investigational tuberculosis vaccine M72/AS01E-4 in people living with HIV.

June 28, 2023 - Bill Gates, the co-chair of the Bill & Melinda Gates Foundation, commented in a press release, "Greater investment in safe and effective TB vaccines alongside a suite of new diagnostics and treatments could transform TB care for millions of people, saving lives and lowering the burden of this devastating and costly disease."

May 10, 2022 - AFP reported that the M72 TB vaccine could save tens of thousands of South African lives yearly.

December 20, 2021 - A Multi-country, Epidemiologic Study to Assess the Interferon Gamma Release Assay (IGRA) Positivity and Build Capacity to Conduct a Tuberculosis (TB) Vaccine Efficacy Study in Populations With a High TB Disease Burden.

June 30, 2020 - The WHO published - Vaccines and Immunization: Investigational vaccine candidate M72/AS01E: FAQs.

January 27, 2020 - London-based GSK announced that it had licensed its M72/AS01E tuberculosis disease vaccine candidate to the Bill & Melinda Gates Medical Research Institute (MRI).

October 29, 2019 -  GSK and IAVI reported that GSK's M72/AS01E candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease (TB) in HIV-negative adults with latent TB infection. These results demonstrate an overall vaccine efficacy of 50% during the three years after vaccination. In addition, the candidate vaccine has an acceptable safety and reactogenicity profile.

September 25, 2018 - Results from the Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis. Conclusions: M72/AS01E provided 54% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease without evident safety concerns. 

Clinical Trial

Clinical Trial NCT01755598: Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals' Candidate TB Vaccine in Adults. The results showed that administering two doses of M72/AS01E successfully reduced the development of active TB disease with 50% efficacy (90% CI, 12 to 71) in HIV-negative adults with latent Mycobacterium tuberculosis infection. A total of 39 participants contributed to the primary vaccine efficacy analysis during three years of follow-up: 13 participants vaccinated with M72/AS01E developed pulmonary TB compared to 26 participants in the placebo group.

Planned clinical trial: TBV02-301: 26,000 adolescents and adults randomized 1:1 to receive two doses of M72/AS01E or placebo / Primary endpoint: preventing bacteriologically confirmed pulmonary TB.

Clinical Trials

No clinical trials found